{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059297","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.818422+00:00","generated_at":"2026-06-15T03:16:20.491049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible","bullets":["Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.","AP-SA02 advanced: second cohort dosed in Staphylococcus aureus bacteremia Ph1b/2a; PJI study start-up activities.","Closed $30M secured convertible credit agreement with Innoviva (largest shareholder) to fund trials and manufacturing.","Q1 loss from operations $(11.3)M vs $(8.8)M a year ago; cash $25.1M vs $14.9M at Dec 31, 2022.","Grant revenue $0.8M from MTEC/DoD; $16.3M total grant funding expected for AP-SA02 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059297","json":"https://secwatch.observer/filing/0001104659-23-059297.json","markdown":"https://secwatch.observer/filing/0001104659-23-059297.md","text":"https://secwatch.observer/filing/0001104659-23-059297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/0001104659-23-059297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/tm2315601d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:16:20.491049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54b1c061198e28eedc0936d13397cb8df5519ffb","claim":"Armata Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023, in the press release furnished hereto as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/0001104659-23-059297-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}